GSIAS
MRKR icon

Garden State Investment Advisory Services’s Marker Therapeutics MRKR Stock Holding History

Garden State Investment Advisory Services’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$2.66K – 234
2022
Q4 		$2.66K Buy
+1,000
New +$3.45K ﹤0.01% 197

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Garden State Investment Advisory Services's MRKR Position: Q1 2023 in Review

Garden State Investment Advisory Services sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 1,000 shares — an estimated $2.66K sold.

Garden State Investment Advisory Services first reported a position in MRKR in Q4 2022 and held it in 1 quarter. The position peaked at $2.66K in Q4 2022. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

  • Garden State Investment Advisory Services reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Garden State Investment Advisory Services sold 1,000 Marker Therapeutics shares in Q1 2023, an estimated $2.66K.
  • Garden State Investment Advisory Services first reported a position in Marker Therapeutics in Q4 2022 and held it in 1 quarter.
  • Garden State Investment Advisory Services's Marker Therapeutics position peaked at $2.66K in Q4 2022.
  • 30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on Garden State Investment Advisory Services's 13F filing for Q1 2023, filed 11 May 2023.